

Morphological Aspects and Treatment Strategies for Chronic Total Occlusions of the Coronary Arteries

Albi Fagu¹, Ormir Shurdha², Nevila Caushi¹, Ketjon Menkshi¹,
Dervish Hasi¹, Meriton Siqeca³

Received: 24 September 2022 / Accepted: 09 November 2022 / Published online: 20 January 2023

This article is published with open access at <https://journal.astes.org.al>

© The author(s) 2023. © The Albanian Journal of Trauma and Emergency Surgery is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License: <http://creativecommons.org/licenses/by-nc/> which permits unrestricted non-commercial use, distribution, and reproduction in any medium provided the original work is properly cited.

Abstract

Coronary total occlusions are routinely found in patients suffering from chronic coronary artery disease. Their prevalence is between 20-50% and is higher in patients with prior coronary artery bypass surgery. Patients with CTOs have a higher risk profile, higher Syntax scores and in approximately 80% of the cases, a multi-vessel disease. Advances in technology that supports CTO-PCI and the increasing operator experience in high volume centers has raised important questions about the revascularization strategy. In the majority of cases, the treatment strategy for this group of patients should aim at achieving full revascularization. In this context CABG should be considered the first choice and percutaneous coronary intervention can be considered for patients with less advanced disease. It is not clear, whether successful CTO revascularization (CABG or PCI) have an impact on long-term outcomes. For these reasons, the treatment of patients in the presence of CTOs should be based on the current evidence on the treatment of multivessel coronary disease.

Keywords: Chronic total occlusions, Coronary artery disease, CTO, CABG, CTO-PCI.

Abbreviations

CTO - Chronic total occlusions; CAD - Coronary Artery Disease; RCA - Right Coronary Artery; LAD - Left Anterior Descending; LCX - Left Circumflex Artery; PCI - Percutaneous Coronary Intervention; CABG - Coronary Artery Bypass Grafting; LV - Left Ventricle

Original article, no submission or publication in advance or in parallel

* Corresponding author:

Albi Fagu MD

✉ albifagu@yahoo.com

1 Cardiac Surgery Clinic, University Hospital "Shefqet Ndroqi", Tirana, ALBANIA

2 Department of Cardiovascular Diseases, University Hospital "Mother Theresa" Tirana, ALBANIA

3 Cardiology Clinic, University Hospital "Shefqet Ndroqi", Tirana, ALBANIA

Introduction

Coronary artery disease (CAD), as a major cause of mortality and disability, is the most addressed pathology by cardiologists and cardiac surgeons worldwide.[1, 2] Coronary artery total occlusions (CTO) are considered to be the highest grade of atherosclerotic involvement of a coronary artery and are considered chronic if older than three months.[3, 4]

Since this process occurs gradually, it gives time to the collateral system to develop and therefore it is consistently found in stable patients with or without symptoms. Occasionally these patients become symptomatic because of the generalized CAD and the CTO is an incidental finding without clear information about the timing of the occlusion event.[5-7]

Large registries or single center series show that the overall prevalence of CTOs in the CAD population ranges between 20-50% and is higher among patients with prior coronary artery bypass surgery (CABG) (Table 1). They affect more often the right coronary artery (RCA) and

involve more than one coronary artery in around 17% of cases.[8–10]

According to the 2018 ESC/EACTS Guidelines on myocardial revascularization, the treatment of patients with coronary disease in the presence of a CTO, may be based on the same principles as those without a CTO. The limited number of randomized controlled trials that analyze the effect of the revascularization of these lesions and the conflicting results, does not allow for more specific recommendations.[11] The majority of patients with CTOs have a higher risk profile, higher Syntax Scores and in approximately 80% of the cases, a multi-vessel disease. [12, 13] In this context, CABG should be considered as the primary treatment strategy and percutaneous coronary intervention (PCI) may be considered in patients with a less extensive CAD (single vessel) or in high-risk patients such as in redo surgery [8, 14, 15].

Current technological and device innovations that facilitate PCI, as well as the increasing operator experience, have generated higher success rates of CTO-PCI. These rates are dependent on center volume, operator skills and specific equipment and vary from 60–90%. [16–18]

The incrementing use of PCI to recanalize CTOs is not based on strong evidence and the success rates reported are only exclusive to high-volume centers. Both revascularization strategies have specific advantages that must be taken into consideration in order to offer an individualized treatment for the patients with CTO.

In this review, we aim to describe the anatomic variability of CTOs, the impact it has in the treatment success and to summarize the existing evidence regarding treatment strategies for this group of patients.

Morphological aspects and their impact on outcomes

CTOs are a common finding in patients undergoing coronary angiographic examinations for stable CAD. [8, 10] The prevalence of CTOs shows a high level of variability in different reports (Table 1) and is higher in patients with advanced disease involving all 3 coronary vessels. The Canadian multicenter CTO registry found that solitary CTOs (not in context of multivessel disease) are found in only 10% of patients and the rest was identified in patients suffering from left main, or multivessel CAD.[10]

CTOs are localized in the RCA in 40–60% of cases and affect the left anterior descending artery (LAD) and the circumflex artery (LCX) almost equally (Table 1).

The occlusions are mostly located in the proximal or middle segment of the artery, but also in the distal portion in the case of LCX (Fig.1).[22] This has important implications in the treatment strategy when choosing between CABG or PCI. In fact, CABG addresses the distal segments of the diseased coronaries, and the localization of the CTO plays a minor role in the revascularization strategy. In the case of CTO-PCI, the revascularization of distal occlusions is avoided and considered not amenable to PCI. In the DECISION-CTO trial, Euro-CTO trial and EXPERT-CTO trial, different inclusion criteria like: “target coronary diameter ≥ 2.5 mm”, or “CTO localized in segments 1–3 for RCA, 6–7 for LAD, 11–12 for LCX are used to exclude the more distal CTO localizations. [23–25] The occluded vessel is almost always perfused by either the ipsilateral or the contralateral coronary artery and the length between the 2 occlusion extremities is considered the CTO length (Fig. 2B). CTOs of the RCA tend to be longer and more angulated than those located in the LAD and LCX. This can be explained by the fact that RCA-CTOs are mostly located at the marginal part of the artery and from this segment originate only small branches that do not influence the progression of the occlusive process. Occlusion length together with other morphological characteristics of the CTO lesion are




Figure 1 Localisation of CTOs according to the coronary segments (Own unpublished data)

Table 1 Prevalence and localization of CTO in the literature

Chronic total occlusion prevalence and location in different studies					
Reference	Study population	CTO prevalence	RCA	LAD	LCX
Kahn et al 1993(19)	333	35%	58%	18%	24%
Toma et al 2017(20) 2002	-	47%	28%	25%	
Tsai et al 2017(21)	111273	26.4%	42.9%	28.1%	29.4%
Christofferson et al 2005 (8)	3087	52%	49.4%	22%	28.6%
Jeroudi et al 2013 (9)	1015	31.3%	-	-	-
Fefer et al (10)	14439	18.2%	46.9%	19.86%	15.43%

CTO: Chronic Total Occlusion; RCA: Right Coronary Artery; LAD: Left Anterior Descending; LCX: Left Circumflex

important predictive factors for the procedural success of CTO-PCI.

In fact, occlusion length of more than 20 mm is related to worse procedural outcomes.[22, 26]

The collateral system

Despite being responsible for the blood perfusion of separate areas of the heart muscle, the coronary arteries “communicate” with an intricate system of inter-arterial anastomoses. In patients with coronary disease, hypertrophy and other diseases that affect the myocardial perfusion, the presence of a collateral system is described in more than 50% of the cases [27, 28]. Collateral arteries can be epicardial or intramuscular and create ipsilateral or contralateral communication between coronary arteries. Ipsilateral collaterals are mostly found when the CTO is localized in the LCX position. In the case of LAD-CTOs and RCA-CTOs they show a higher tendency towards contralateral collateral formation (Fig.2).[22]

There are visible, functioning collaterals ($>0,5$ mm) and potentially recruitable collaterals (<100 μ m). The

latter are almost invisible in the absence of occlusion and develop into important collaterals when coronary occlusion is present [29]

The collateralization of the occluded coronaries helps in preventing myocardial infarction and in preserving the left ventricular function in as much as 50% of cases. Only 17-20% of the cases present with a severely reduced left ventricular function [5, 8, 10].

On the other hand, despite a well-developed collateralization and almost normal contractility, this area of myocardium is under perfused and ischemic. Because of the reduced functional reserve of the collateral system these patients become often symptomatic during activity. The presence of a good functioning collateral system is not a guarantee for a preserved viability. It is found both in patients with large dysfunctional areas and in patients with preserved left ventricular function [30, 31].

Cardiovascular profile of patients with CTO

Patients with chronic occluded arteries differ considerably




Figure 2 Collateralization of CTOs; A: CTO of the right coronary artery, septal and apical collaterals; B: CTO of the posterolateral branch of the circumflex artery, epicardial, lateral wall collaterals; C: multiple CTOs; D: CTO of the left anterior descending, apical and septal collaterals. (Own database)

from other CAD patients. They are generally older and have higher SYNTAX Scores. Approximately 80% of these patients have a multivessel disease and in 7-10% the left main artery is involved, generally with severe calcification of the coronaries. The LV function may be preserved in as much as 50% of patients, but the rest presents with extensive LV scarring and with different grades of residual viability in the infarcted area.[32] They also have more often other comorbidities such as hypertension, diabetes, and peripheral vascular disease. CTO patients are more often smokers, overweight and have dyslipidemia [8, 10, 14].

Viability assessment

There is conflicting evidence regarding the value of preprocedural and preoperative viability assessment. In a meta-analysis, Allman et al.[33] showed improvement in outcomes after revascularization in patients with LV dysfunction and viable myocardium, but not in the absence of viability. A randomized trial from Beanlands et al. (PARR-2), failed to support the importance of viability testing in patients with severe LV dysfunction.[34]

There is a general consent that the assessment of myocardial viability is a prerequisite for the revascularization of patients with severely reduced LV Function. The recommendation to objectify the viability of the “collateralized” area of the CTO makes more sense in the case of the CTO-PCI. The recanalization of a CTO with PCI is a complex procedure associated with longer procedural times, increased risk of complications and adverse outcomes [13, 17, 35]. On the other hand, the treatment of CTOs with CABG does not require specific techniques to be performed and achieves comparable results with respect to other CAD patients. [36, 37] The majority of patients with a CTO that are treated with CABG have a 3-vessel disease, and the decision to bypass the occluded artery does not have an impact on the complexity of the procedure.

CABG for the treatment of CTOs

The recommendation for surgical treatment of patients with advanced CAD is based on the results of different randomized trials.[12, 38] Patients with multivessel disease and in the presence of CTOs are preferably assigned to CABG. The SYNTAX Trial demonstrated that the surgical revascularization of patients with multivessel disease, left main disease and those with CTOs is associated with better outcomes when compared with PCI. The difference in outcomes was more significant in patients with higher SYNTAX scores including those with CTOs. [12] The use of arterial grafts and the tendency towards complete revascularization has a positive impact on the results achieved by CABG.

Techniques of bypassing CTO vessels do not differ from CABG of other coronary lesions. However, in our

experience it is sometimes mandatory to anastomose the vessel in its most distal part, especially in the case of long CTO lesions. Coronary endarterectomy for the treatment of the occluded vessel is rarely needed and does not offer good long-term results [39–41]

The mortality and morbidity of CABG have decreased substantially over time. Mortality rates of 1-3% and stroke rates 0.5-1.5% show that CABG can be considered a low-risk procedure. [42, 43] For the abovementioned reasons, CABG should be the first therapeutic choice for patients presenting with advanced CAD and particularly in the presence of a CTO.

PCI for the treatment of CTOs

CTO-PCI is being increasingly used in dedicated centers and there is a tendency to replace CABG for this purpose. Advances in technology that supports CTO-PCI and the increasing operator experience in high volume centers has resulted in increasing recanalization success rates.[16, 44] The actual evidence is mostly based on observational studies and no RCTs have confirmed its efficacy compared to surgery. The Euro-CTO trial compared CTO-PCI plus medical treatment vs medical treatment alone for patients with CTOs. The principal findings were improved angina frequency scores and quality of life scores for the PCI group. Cardiovascular death and myocardial infarction events were similar after 3 years but MACCEs were significantly lower in the PCI group.[25] The Decision-CTO trial compared outcomes between 2 treatment strategies for patient being treated with PCI when CTOs were present: recanalization of the CTO vs no recanalization of the CTO. This trial showed no differences in the incidence of major cardiovascular events and in the quality of life.[23]

A meta-analysis of patients with stable obstructive coronary artery disease treated either with PCI and medical treatment or medical treatment alone showed no differences regarding death, MI, need for repeat revascularization, or angina.[45]

Also, angiographic evidence of the patency of recanalized CTO vessels is scarce. Different reports show that re-occlusions or restenosis after successful CTO-PCI can occur in as much as 50% of cases, thus raising important questions regarding the efficacy of the procedure.[46, 47]

CTO-PCI is a complicated and very invasive procedure associated with increased exposure times, increased use of contrast and increased incidence of renal failure.[48] Other factors that should be considered when choosing this treatment strategy are: increased risk for coronary perforation and the resulting tamponade, coronary dissections, distal coronary micro embolism that can occlude an otherwise functioning collateralized vessel and the increased procedural mortality in comparison with normal PCI.

Revascularization rates

Revascularization rates of the CTOs vary considerably depending on the treatment strategy and local expertise. In the case of CTO-PCI, this variability is more pronounced because of the increased complexity of the procedure in comparison to routine PCI procedures and in this case operator experience and center volume play an important role. Jones et al, investigated the impact successful revascularization had on mortality and described revascularization rates of 69.6%. The multivariate analysis demonstrated that failed revascularization was predictive of worse outcomes.[49] In a meta-analysis from Patel et al. that included 18061 patients, successful revascularization of CTOs was achieved in 77% of cases and the failed CTO-PCI was associated with worse outcomes. Publications comparing successful with non-successful CTO-PCI and their impact on outcomes should be interpreted cautiously. The fact that failed CTO-PCI is related to worse outcomes does not necessarily mean that successful CTO recanalization have a positive impact. In fact, attempted and failed CTO recanalization imply an increased level of invasiveness compared to successful CTO-PCI, with coronary dissections, bleeding complications and urgent surgery being the typical complications.[50]

From the other side, the treatment of CTOs with CABG does not require additional technical efforts and technology and from a certain point is less influenced by operator experience and center volume. In a study from Banerjee et al. the authors were able to demonstrate that CABG achieves high CTO revascularization rates (100% for LAD CTOs, 92% for LCX and RCA).[51]

Fefer et al, reported similar revascularization rates in a report of 405 patients, with 100% successful revascularization in the case of LAD-CTO.[52] No clear evidence exists regarding the impact of CTO revascularization in the results of patients being treated with CABG. In fact, the rationale for the surgical CTO revascularization is based on the intention to achieve full revascularization and the confirmed impact it has on outcomes.[53, 54]

Conclusion

It is not clear, whether successful CTO revascularization (CABG or PCI) have an impact on long-term outcomes of patients being treated for CAD. For these reasons, the treatment of patients in the presence of CTOs should be based on the current evidence on the treatment of multivessel coronary disease. Evidence comparing different treatment strategies for the treatment of CTOs and evaluating their impact on long-term outcomes is scarce and does not allow for specific recommendations. Comparing outcomes between successful and not successful CTO-PCI and using high revascularization

rates as a measure to compare CTO-PCI with CABG, cannot provide clear evidence about treatment options. There is an increasing need for a randomized controlled trial comparing CTO-PCI with CABG or evaluating the impact CTO revascularization has on outcomes.

COI Statement: This paper has not been submitted in parallel. It has not been presented fully or partially at a meeting or podium or congress. It has not been published nor submitted for consideration beforehand.

This research received no specific grant from any funding agency in the public, commercial, or non-profit sectors. There are no relevant or minor financial relationships from authors, their relatives or next of kin with external companies.

Disclosure: The authors declared no conflict of interest. No funding was received for this study.

References

1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. *Circulation*. 2017 Jan 1;
2. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European Cardiovascular Disease Statistics 2017 edition. European Heart Network, Brussels. 2017;192.
3. Strydom HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, et al. A Definition of Advanced Types of Atherosclerotic Lesions and a Histological Classification of Atherosclerosis. *Circulation* [Internet]. 1995 Sep 1 [cited 2022 Sep 11];92(5):1355–74. Available from: <https://www.ahajournals.org/doi/abs/10.1161/01.CIR.92.5.1355>
4. Mario C Di, Werner GS, Sianos G, Galassi AR, Büttner J, Dudek D, et al. European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. *EuroIntervention*. 22AD May;3(1):30–43.
5. Maseri A, Chierchia S, Davies G. Pathophysiology of coronary occlusion in acute infarction. *Circulation*. 1986;73(2):233–9.
6. Galassi AR, Werner GS, Boukhris M, Azzalini L, Mashayekhi K, Carlino M, et al. Percutaneous recanalisation of chronic total occlusions: 2019 consensus document from the EuroCTO Club. *EuroIntervention*. 2019 Jun;15(2):198–208.
7. Bardají A, Rodríguez-López J, Torres-Sánchez M. Chronic total occlusion: To treat or not to treat. *World J Cardiol*. 2014 Jul 26;6(7):621–9.
8. Christofferson RD, Lehmann KG, Martin G v., Every N, Caldwell JH, Kapadia SR. Effect of chronic total coronary occlusion on treatment strategy. *American Journal of Cardiology* [Internet]. 2005 May 1 [cited 2021 Jan 5];95(9):1088–91. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0002914905001906>
9. Jeroudi OM, Alomar ME, Michael TT, Sabbagh A el, Patel VG, Mogabgab O, et al. Prevalence and management of coronary chronic total occlusions in a tertiary veterans affairs hospital. *Catheterization and Cardiovascular Interventions*

- [Internet]. 2014 Oct 1 [cited 2021 Mar 23];84(4):637–43. Available from: <https://pubmed.ncbi.nlm.nih.gov/24142769/>
10. Fefer P, Knudtson ML, Cheema AN, Galbraith PD, Oshero AB, Yalonetsky S, et al. Current perspectives on coronary chronic total occlusions: The Canadian multicenter chronic total occlusions registry. *J Am Coll Cardiol* [Internet]. 2012 Mar 13 [cited 2021 Mar 23];59(11):991–7. Available from: <http://dx.doi.org/10.1016/j.jacc.2011.12.007>
 11. Sousa-Uva M, Neumann FJ, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *European Journal of Cardiothoracic Surgery* [Internet]. 2019 Jan 1 [cited 2020 Nov 8];55(1):4–90. Available from: <https://academic.oup.com/ejcts/article/55/1/4/5079878>
 12. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. *New England Journal of Medicine*. 2009 Mar 5;360(10):961–72.
 13. Tajti P, Brilakis ES. Chronic total occlusion percutaneous coronary intervention: Evidence and controversies. *J Am Heart Assoc*. 2018;7(2):1–15.
 14. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *New England Journal of Medicine*. 2009 Mar 5;360(10):961–72.
 15. Zakkar M, George SJ, Ascione R. Should chronic total occlusion be treated with coronary artery bypass grafting? Chronic total occlusion should be treated with coronary artery bypass grafting. *Circulation*. 2016;133(18):1807–16.
 16. Toma A, Stähli BE, Gick M, Colmsee H, Gebhard C, Mashayekhi K, et al. Long-Term Follow-Up of Patients with Previous Coronary Artery Bypass Grafting Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion. *American Journal of Cardiology* [Internet]. 2016;118(11):1641–6. Available from: <http://dx.doi.org/10.1016/j.amjcard.2016.08.038>
 17. Brilakis ES, Banerjee S, Karpaliotis D, Lombardi WL, Tsai TT, Shunk KA, et al. Procedural outcomes of chronic total occlusion percutaneous coronary intervention: A report from the NCDR (National Cardiovascular Data Registry). *JACC Cardiovasc Interv*. 2015 Feb 1;8(2):245–53.
 18. Winter MP, Goliash G, Bartko P, Siller-Matula J, Ayoub M, Aschauer S, et al. Left Main Coronary Artery Disease and Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions. *J Clin Med*. 2020 Mar 30;9(4):938.
 19. Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. *Am Heart J*. 1993 Sep 1;126(3 PART 1):561–4.
 20. Toma A, Stähli BE, Gick M, Gebhard C, Kaufmann BA, Mashayekhi K, et al. Comparison of Benefit of Successful Percutaneous Coronary Intervention for Chronic Total Occlusion in Patients with Versus Without Reduced ($\leq 40\%$) Left Ventricular Ejection Fraction. *American Journal of Cardiology*. 2017 Nov 15;120(10):1780–6.
 21. Tsai TT, Stanislawski MA, Shunk KA, Armstrong EJ, Grunwald GK, Schob AH, et al. Contemporary Incidence, Management, and Long-Term Outcomes of Percutaneous Coronary Interventions for Chronic Coronary Artery Total Occlusions: Insights from the VA CART Program. *JACC Cardiovasc Interv*. 2017 May 8;10(9):866–75.
 22. HASEGAWA T, GODINO C, BASAVARAJIAH S, TAKAGI K, REZQ A, LATIB A, et al. Differences in the Clinical and Angiographic Characteristics of Chronic Total Occlusion Lesions in the Three Major Coronary Arteries. *J Interv Cardiol* [Internet]. 2014 Feb 1 [cited 2021 Feb 22];27(1):44–9. Available from: <http://doi.wiley.com/10.1111/joic.12085>
 23. Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, et al. Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion: The DECISION-CTO Trial. *Circulation* [Internet]. 2019 Apr 2 [cited 2021 Mar 1];139(14):1674–83. Available from: <http://ahajournals.org>
 24. Kandzari DE, Kini AS, Karpaliotis D, Moses JW, Tummala PE, Grantham JA, et al. Safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization: Results from the EXPERT CTO multicenter trial (evaluation of the XIENCE coronary stent, performance, and technique in chronic total occlusions). *JACC Cardiovasc Interv*. 2015 May 1;8(6):761–9.
 25. Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. *Eur Heart J* [Internet]. 2018 Jul 7 [cited 2021 Jan 4];39(26):2484–93. Available from: <https://pubmed.ncbi.nlm.nih.gov/29722796/>
 26. Morino Y, Abe M, Morimoto T, Kimura T, Hayashi Y, Muramatsu T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: The J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. *JACC Cardiovasc Interv* [Internet]. 2011 Feb [cited 2022 Sep 12];4(2):213–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/21349461/>
 27. Seiler C, Stoller M, Pitt B, Meier P. The human coronary collateral circulation: Development and clinical importance. *Eur Heart J*. 2013;34(34):2674–82.
 28. Pitt B. Interarterial Coronary Anastomoses Occurrence in Normal Heart and in Certain Pathologic Conditions. *Circulation*. 1959; XX(November):816–22.
 29. Seiler C. Collateral Circulation of the Heart. Springer-Verlag London; 2009. 235–303 p.
 30. Azzalini L, Torregrossa G, Puskas JD, Brilakis ES, Lombardi WL, Karpaliotis D, et al. Percutaneous revascularization of chronic total occlusions: Rationale, indications, techniques, and the cardiac surgeon's point of view. *Int J Cardiol*. 2017;
 31. Werner GS. The role of coronary collaterals in chronic total occlusions. *Curr Cardiol Rev*. 2014;10(1).
 32. Wijns W, Vatner SF, Camici PG. Mechanisms of disease: Hibernating myocardium. *New England Journal of Medicine*. 1998;339(3).
 33. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. *J Am Coll Cardiol*.

- 2002 Apr 3;39(7):1151–8.
34. Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients with Severe Left Ventricular Dysfunction and Suspected Coronary Disease. A Randomized, Controlled Trial (PARR-2). *J Am Coll Cardiol*. 2007 Nov 13;50(20):2002–12.
 35. Zakkar M, George SJ, Ascione R. Should chronic total occlusion be treated with coronary artery bypass grafting? Chronic total occlusion should be treated with coronary artery bypass grafting. *Circulation*. 2016;133(18):1807–16.
 36. Zakkar M, George SJ, Ascione R, Weintraub WS, Garratt KN. Should chronic total occlusion be treated with coronary artery bypass grafting? Chronic total occlusion should be treated with coronary artery bypass grafting. *Circulation*. 2016 May 3;133(18):1807–16.
 37. Weintraub WS, Garratt KN. Should Chronic Total Occlusion Be Treated with Coronary Artery Bypass Grafting? *Circulation*. 2016;133(18):1818–25.
 38. Mäkikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IBA, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *The Lancet* [Internet]. 2016 Dec 3 [cited 2020 Oct 26];388(10061):2743–52. Available from: <http://www.thelancet.com/article/S0140673616320529/fulltext>
 39. Sundt TM, Camillo CJ, Mendeloff EN, Barner HB, Gay WA. Reappraisal of coronary endarterectomy for the treatment of diffuse coronary artery disease. In: *Annals of Thoracic Surgery*. Elsevier; 1999. p. 1272–7.
 40. Ghatanatti R, Teli A. Coronary endarterectomy: Recent trends. Vol. 11, *Journal of Clinical and Diagnostic Research*. Journal of Clinical and Diagnostic Research; 2017. p. PE01–4.
 41. Gill IS, Beanlands DS, Boyd WD, Finlay S, Keon WJ. Left anterior descending endarterectomy and internal thoracic artery bypass for diffuse coronary disease. *Annals of Thoracic Surgery*. 1998 Mar;65(3):659–62.
 42. Brewer R, Theurer PF, Cogan CM, Bell GF, Prager RL, Paone G. Morbidity but not mortality is decreased after off-pump coronary artery bypass surgery. *Ann Thorac Surg* [Internet]. 2014 Mar [cited 2022 Sep 13];97(3):831–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/24200395/>
 43. Bowdish ME, D’Agostino RS, Thourani VH, Desai N, Shahian DM, Fernandez FG, et al. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2020 Update on Outcomes and Research. *Ann Thorac Surg* [Internet]. 2020 Jun 1 [cited 2022 Jan 13];109(6):1646–55. Available from: <http://www.annalthoracicsurgery.org/article/S0003497520304264/fulltext>
 44. Jang Y, Won H. History of CTO Intervention and Benefits of CTO PCI. In: *Percutaneous Coronary Interventions for Chronic Total Occlusion* [Internet]. Singapore: Springer Singapore; 2019 [cited 2021 Mar 13]. p. 1–7. Available from: http://link.springer.com/10.1007/978-981-10-6026-7_1
 45. Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. *JAMA Intern Med* [Internet]. 2014 Feb [cited 2022 Sep 13];174(2):232–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/24296791/>
 46. Valenti R, Vergara R, Migliorini A, Parodi G, Buonamici P, Cerisano G, et al. Comparison of everolimus-eluting stent with paclitaxel-eluting stent in long chronic total occlusions. *Am J Cardiol* [Internet]. 2011 Jun 15 [cited 2022 Sep 13];107(12):1768–71. Available from: <https://pubmed.ncbi.nlm.nih.gov/21529743/>
 47. Valenti R, Vergara R, Migliorini A, Parodi G, Carrabba N, Cerisano G, et al. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. *J Am Coll Cardiol* [Internet]. 2013 Feb 5 [cited 2022 Sep 13];61(5):545–50. Available from: <https://pubmed.ncbi.nlm.nih.gov/23273395/>
 48. Galassi AR, Sianos G, Werner GS, Escaned J, Tomasello SD, Boukhris M, et al. Retrograde Recanalization of Chronic Total Occlusions in Europe. *J Am Coll Cardiol* [Internet]. 2015 Jun 9;65(22):2388 LP – 2400. Available from: <http://www.onlinejacc.org/content/65/22/2388.abstract>
 49. Jones DA, Weerackody R, Rathod K, Behar J, Gallagher S, Knight CJ, et al. Successful recanalization of chronic total occlusions is associated with improved long-term survival. *JACC Cardiovasc Interv* [Internet]. 2012 Apr [cited 2022 Sep 14];5(4):380–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/22516393/>
 50. Fang HY, Lu SY, Lee WC, Lin YS, Cheng CI, Chen CJ, et al. The predictors of successful percutaneous coronary intervention in ostial left anterior descending artery chronic total occlusion. *Catheterization and Cardiovascular Interventions* [Internet]. 2014 Oct 1 [cited 2022 Sep 26];84(4):E30–7. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/ccd.25514>
 51. Banerjee S, Master RG, Peltz M, Willis B, Mohammed A, Little BB, et al. Influence of chronic total occlusions on coronary artery bypass graft surgical outcomes. *J Card Surg*. 2012 Nov;27(6):662–7.
 52. Fefer P, Gannot S, Kochkina K, Maor E, Matetzky S, Raanani E, et al. Impact of coronary chronic total occlusions on long-term mortality in patients undergoing coronary artery bypass grafting. 2014 [cited 2021 Jul 2]; Available from: <https://reference.medscape.com/medline/abstract/24618056>
 53. Farooq V, Serruys PW, Garcia-Garcia HM, Zhang Y, Bourantas C v., Holmes DR, et al. The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: The SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. *J Am Coll Cardiol* [Internet]. 2013 Jan 22 [cited 2021 Apr 12];61(3):282–94. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0735109712053727>
 54. Serruys PW, Morice MCC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *New England Journal of Medicine* [Internet]. 2009 Mar 5 [cited 2020 Oct 25];360(10):961–72. Available from: <https://pubmed.ncbi.nlm.nih.gov/19228612/>